(Q35570387)

8 August 2017

1 reference

reason for preferred rank

title

Why do phase III trials of promising heart failure drugs often fail? the contribution of “regression to the truth” (English)

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

26 March 2024

Why do phase III trials of promising heart failure drugs often fail? The contribution of "regression to the truth" (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583896

Cardiology and cardiovascular medicine

26 March 2024

main subject

phase III clinical trial

0 references

heart failure

1 reference

based on heuristic

inferred from title

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

26 March 2024

1

Henry Krum

1 reference

8 August 2017

2

Andrew Tonkin

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14583896

26 March 2024

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S1071916403000186?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

https://api.elsevier.com/content/article/PII:S1071916403000186?httpAccept=text/plain

26 March 2024

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Journal of Cardiac Failure

26 March 2024

published in

1 reference

8 August 2017

volume

9

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

364-367

1 reference

Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?

26 March 2024

2

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

26 March 2024

3

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

26 March 2024

4

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

26 March 2024

5

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure

26 March 2024

7

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

26 March 2024

8

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

26 March 2024

9

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

26 March 2024

10

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

26 March 2024

11

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT

26 March 2024

12

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.

26 March 2024

13

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

26 March 2024

14

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

26 March 2024

15

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

26 March 2024

16

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial

26 March 2024

17

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure

26 March 2024

18

1 reference

https://api.crossref.org/works/10.1054/S1071-9164(03)00018-6

26 March 2024

Identifiers

1 reference

8 August 2017

1 reference